- Home
- CRBU vs SEER Comparison
CRBU vs SEER Comparison
Compare CRBU & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- SEER
- Stock Information
- Founded
- CRBU 2011
- SEER 2017
- Country
- CRBU United States
- SEER United States
- Employees
- CRBU N/A
- SEER N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- SEER Medicinal Chemicals and Botanical Products
- Sector
- CRBU Health Care
- SEER Health Care
- Exchange
- CRBU Nasdaq
- SEER Nasdaq
- Market Cap
- CRBU 151.2M
- SEER 135.0M
- IPO Year
- CRBU 2021
- SEER 2020
- Fundamental
- Price
- CRBU $1.52
- SEER $2.36
- Analyst Decision
- CRBU Strong Buy
- SEER Hold
- Analyst Count
- CRBU 5
- SEER 1
- Target Price
- CRBU $11.80
- SEER $3.00
- AVG Volume (30 Days)
- CRBU 1.6M
- SEER 200.2K
- Earning Date
- CRBU 03-10-2025
- SEER 02-27-2025
- Dividend Yield
- CRBU N/A
- SEER N/A
- EPS Growth
- CRBU N/A
- SEER N/A
- EPS
- CRBU N/A
- SEER N/A
- Revenue
- CRBU $11,475,000.00
- SEER $14,608,000.00
- Revenue This Year
- CRBU N/A
- SEER N/A
- Revenue Next Year
- CRBU N/A
- SEER $34.78
- P/E Ratio
- CRBU N/A
- SEER N/A
- Revenue Growth
- CRBU N/A
- SEER N/A
- 52 Week Low
- CRBU $1.50
- SEER $1.51
- 52 Week High
- CRBU $8.33
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- CRBU 34.82
- SEER 51.66
- Support Level
- CRBU $1.50
- SEER $2.26
- Resistance Level
- CRBU $1.69
- SEER $2.37
- Average True Range (ATR)
- CRBU 0.13
- SEER 0.11
- MACD
- CRBU -0.01
- SEER -0.01
- Stochastic Oscillator
- CRBU 3.70
- SEER 61.43
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.